Long-Term Follow-up of Patients Treated With Miltenyi Cell and Gene Therapies

ConditionsMelanoma Stage III B-cell Non Hodgkin Lymphoma Pediatric ALL Childhood Non-Hodgkin Lymphoma Acute Lymphatic Leukemia Chronic Lymphatic Leukemia Melanoma Stage IV

Trial statusRecruiting

Trial phaseNot applicable

Trial typeInterventional

Biological sexAll

AgeNot listed

SponsorMiltenyi Biomedicine GmbH

About this trial

The goal of this Long-Term Follow-Up Trial is to assess long-term safety and efficacy of Miltenyi CAR T treatment.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Patient underwent treatment with a Miltenyi CAR T cell therapy in one of the parent trials at least 12 months prior to enrollment in long-term follow-up.

Patient has provided informed consent prior to enrollment.

Disqualifiers

No exclusion criteria

Trial design

Design model

Single group

Treatments tested in this trial

MB-CART19.1
Biological/Vaccine
Assessment of long-term safety and efficacy of MB-CART19.1 treatment.
MB-CART20.1
Biological/Vaccine
Assessment of long-term safety and efficacy of MB-CART20.1 treatment.
MB-CART2019.1
Biological/Vaccine
Assessment of long-term safety and efficacy of MB-CART2019.1 treatment.

Treatment groups

40 Participants

are divided into 1 treatment group

Group A: Long-term follow-up of CAR T cell therapyExperimental treatment 3 interventions

Trial outcomes

Primary outcomes

Adverse Events

Percentage of patients with late-onset adverse reactions (AR), serious adverse events (SAE), serious adverse reactions (SAR) and adverse events of special interest (AESI) including relapse or progression of the underlying disease, life-threatening infections, death due to any cause, new and secondary malignancies

Time frame